You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic does not review or control the content on the other website, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in the United Kingdom.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Multidisciplinary collaboration for cryptogenic stroke care
A Cryptogenic Stroke Pathway is a consistent approach to a follow-up plan and transition of care for patients with a stroke of unknown source. This implementation guide is intended to extend your acute stroke protocol to include a monitoring plan for cryptogenic stroke patients. It includes monitoring for AF with the best monitoring mechanisms available to optimise outcomes.
After initial stroke discharge, many patients are not receiving any additional cardiac monitoring. Establishing a monitoring pathway to detect and treat AF can significantly reduce a patient’s risk for another stroke. The ability to identify AF in patients with cryptogenic stroke has profound implications for long-term medical management.
Many cryptogenic stroke patients are lost to follow-up. Pathways for transition of care and follow-up help to ensure these patients receive better care.
A Cryptogenic Stroke Pathway allows all healthcare professionals involved in the continuum to ensure a standard of care. Through this pathway, hospitals can:
When developing the Cryptogenic Stroke Pathway, it is important to involve all stakeholders involved in the care of the patient.
Medtronic Disclosure Statement: This pathway is provided for educational purposes and should not be considered the exclusive source for this type of information. It is the responsibility of the practitioner to exercise independent clinical judgment.
Refer to the brief statement for indications, warnings/precautions, and complications for the Reveal LINQ ICM.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. September 1987;147(9):1561-1564.
Lin HJ, Kelly-Hayes M, Beiser AS, et al. Stroke Severity in Atrial Fibrillation: The Framingham Study. Stroke. 1996; 27: 1760-1764.
Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. August 1991;84(2):527-539.